Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results

Matching calls

After selected filters

Transcript verified

Official transcript summaries on this page

Preliminary briefs

Presentation evidence, clearly labelled

Processing

Transcript filed or call source found

Tracked companies

Watchlist or portfolio matches

Management evidence

Generated 5 Nov, 5:56 am IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters

Company	Call and sources	Reported result	Management outlook	Evidence-led conclusion	Review
LAURUSLABS Laurus Labs Limited Pharma · Mid	Sept 2026 3 Nov 2026 Transcript verified Transcript PPT Recording	Excellent 100/100	Optimistic outlook No comparable prior call Guidance maintained	Laurus Labs delivered record quarterly performance in Q2 FY27 with revenue of INR2,206.4 crores and PAT of INR436.2 crores, supported by robust growth in the CDMO and affordable medicines segments, alongside margin expansion. Management maintains a disciplined approach to ongoing growth investments, technology integration, and capacity expansion. Evidence summary ready

Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Transcript-verified summaries rank above preliminary presentation briefs and source-only call evidence. Preliminary briefs are replaced automatically when an official transcript is processed. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.